Adare Pharma Solutions Appoints Tom Sellig CEO

Adare Pharma Solutions, a global, technology-driven contract development and manufacturing organization (CDMO), has appointed Tom Sellig as Chief Executive Officer. Sellig, a 30-year veteran of the pharmaceutical and life sciences industries, will lead the organization in supporting pharmaceutical companies in the development and manufacturing of medicines.
 
Sellig has 30 years of executive experience in life sciences, with a focus on CDMO. He served as Chief Executive Officer of LabConnect, a global provider of central lab and support services for the biopharmaceutical industry. Prior to LabConnect, Sellig was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient-support and patient-access company. Before joining ConnectiveRx, he served as Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Earlier in his career, he served as Global Vice President of Sales and Client Services at Covance.
 
Adare offers technology-driven solutions to help solve challenges from product development to commercial scale manufacturing and packaging. Adare has developed technologies that enable the production of critical pharmaceuticals, including technologies for taste masking, controlled release, and precision injectable delivery. Adare’s recently expanded service offerings include a high potency suite for pilot and commercial scale high potency projects and extensive packaging capabilities from high-speed bottle filling to stick pack and blister packaging.
 
“Tom’s track record of driving commercial and operational excellence in pharmaceutical services uniquely prepares him to lead Adare, at a moment when pharmaceutical companies are increasingly seeking partners to solve their most complex formulation and commercialization challenges,” said Vivek Sharma, who resumes his position as Chairman and Board Director after serving as the company’s interim CEO.

“This is a watershed moment when pharmaceutical and biotech companies are introducing transformative medications into market,” said Sellig. “Adare has developed innovative solutions that make these medicines more widely and readily available to patients through our partnerships with leading pharmaceutical companies. I could not be more excited to join such a talented team as we help widen access to critical healthcare.”
 
Sellig’s appointment follows Adare’s recent acquisition of Frontida BioPharm, which expanded Adare’s global footprint to seven manufacturing and R&D sites dedicated to contract services for the pharmaceutical industry.